does tirzepatide have sulfa in it Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort PDB-101: Diabetes Mellitus: Diabetes Mellitus:

There were 17 NAION events in the GLP-1 group compared to 6 in the non-GLP-1 RA group

For bloating, the answer is more nuanced because bloating during GLP-1 use has multiple different causes, and probiotics only address some of them

Gradual dose reduction may help stabilize appetite signals during the transition

The weight loss guarantee gives peace of mind for people worried about spending without seeing results

Safety depends on several factors, including: Potential side effects may include: Because peptide therapy is still evolving, it is important to work with experienced medical providers who understand regenerative medicine and peptide protocols